Ocular Therapeutix (OCUL) Raw Materials (2014 - 2026)

Ocular Therapeutix's quarterly Raw Materials came in at $287000.0 in Q1 2026, up 53.48% year-on-year from $187000.0 in Q1 2025, and up 42.08% quarter-over-quarter from $202000.0 in Q4 2025.

Ocular Therapeutix has reported Raw Materials for 13 years, with the latest figure at $287000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Raw Materials rose 53.48% year-over-year to $287000.0; the trailing twelve-month figure through Mar 2026 stood at $287000.0 (up 53.48% YoY), and the FY2025 full-year result was $202000.0, down 5.61% from the prior year.
  • Raw Materials for Q1 2026 stood at $287000.0, up from $202000.0 in the prior quarter.
  • The five-year high for Raw Materials was $341000.0 in Q2 2023, with the low at $187000.0 in Q1 2025.
  • Average Raw Materials over 5 years is $269235.3, with a median of $287000.0 recorded in 2026.
  • Year-over-year, Raw Materials plunged 43.16% in 2025 and soared 53.48% in 2026.
  • Tracing OCUL's Raw Materials over 5 years: stood at $309000.0 in 2022, then retreated by 2.27% to $302000.0 in 2023, then decreased by 29.14% to $214000.0 in 2024, then slipped by 5.61% to $202000.0 in 2025, then jumped by 42.08% to $287000.0 in 2026.
  • The last three Raw Materials figures came in at $287000.0 (Q1 2026), $202000.0 (Q4 2025), and $229000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Ocular Therapeutix 1.99 Bn 1.99 Bn 9.46 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 287,000.00
Dec 31, 2025 202,000.00
Sep 30, 2025 229,000.00
Jun 30, 2025 219,000.00
Mar 31, 2025 187,000.00
Dec 31, 2024 214,000.00
Sep 30, 2024 196,000.00
Jun 30, 2024 267,000.00
Mar 31, 2024 329,000.00
Dec 31, 2023 302,000.00
Sep 30, 2023 293,000.00
Jun 30, 2023 341,000.00
Mar 31, 2023 228,000.00
Dec 31, 2022 309,000.00
Sep 30, 2022 317,000.00
Jun 30, 2022 325,000.00
Mar 31, 2022 332,000.00
Dec 31, 2021 388,000.00
Sep 30, 2021 370,000.00
Jun 30, 2021 347,000.00
Mar 31, 2021 373,000.00
Dec 31, 2020 384,000.00
Sep 30, 2020 333,000.00
Jun 30, 2020 235,000.00
Mar 31, 2020 200,000.00
Dec 31, 2019 217,000.00
Dec 31, 2018 112,000.00
Dec 31, 2017 68,000.00
Dec 31, 2016 58,000.00
Dec 31, 2015 75,000.00
Dec 31, 2014 95,000.00